• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Regenerative Medicine

Cambridge Endo and Stemgent bring in several million in new funding rounds

May 18, 2010 By MassDevice staff Leave a Comment

Cambridge Endo, Stemgent logos

Cambridge Endoscopic Devices Inc. and Stemgent Inc. each made quick gains from multi-million dollar equity offerings that opened April 30.

Cambridge Endo, an endoscopic surgical tool maker based in Framingham, Mass., sold to one individual $3 million of a $7.5 million offering, according to Securities & Exchange Commission filings. CEO Woojin Lee and directors Walter Winshall and Phil Henderson were listed as principals in the deal.

Filed Under: Biotech, Business/Financial News, Endoscopic, News Well, Stem Cells Tagged With: Cambridge Endoscopic Devices Inc., Stemgent

Stemgent, Miltenyi Biotec ink strategic alliance

May 4, 2010 By MassDevice staff Leave a Comment

Stemgent, MACs logos

Stemgent Inc. and Germany-based Miltenyi Biotec inked a strategic partnership deal that will see the firms co-develop and market stem cell products.

Under the terms of the agreement, Miltenyi Biotec will be responsible for the overseas marketing and sale of Stemgent’s existing stem cell reagents, antibodies and other products, with Stemgent continuing to serve its U.S. customers. Both companies will begin to jointly develop new products, which Miltenyi Biotec will then commercialize.

Filed Under: Biotech, Business/Financial News, News Well, Stem Cells Tagged With: Miltenyi Biotec, Stemgent

Cellular Dynamics reveals plans for $41 million funding round

April 28, 2010 By MedCity News Leave a Comment

MedCity News logo

By Brandon Glenn

Ending months of silence, Cellular Dynamics International Inc. is finally talking about its nearly $41 million funding round that it says makes it the player with the deepest pockets in the stem cell arena.

Filed Under: Biotech, Business/Financial News, News Well, Stem Cells Tagged With: Cellular Dynamics International Inc.

Juventas Therapeutics launches clinical trial for stem cell factor in heart failure

April 6, 2010 By MedCity News Leave a Comment

MedCity News logo

By Mary Vanac

Clinical-stage regenerative medicine company Juventas Therapeutics Inc. — a Cleveland Clinic spin-out initially named AcelleRX Therapeutics Inc. — started enrolling patients in a Phase 1 clinical trial to evaluate the safety and efficacy of its leading stem cell factor for treating heart failure.

Filed Under: Biotech, Business/Financial News, News Well, Stem Cells Tagged With: Juventas Therapeutics Inc.

Aastrom Biosciences winds up treatment stage of Phase 2 clinical trial

March 9, 2010 By MedCity News Leave a Comment

By Brandon Glenn

Aastrom Biosciences Inc. (NSDQ:ASTMD) finished treating patients in a Phase 2 clinical trial of its cardiac-repair stem cells.

The milestone clears the way for Aastrom to report six-month interim results of the trial later this year, according to a press release.

In the trial, Aastrom treated 40 patients suffering from dilated cardiomyopathy, a severe form of congestive heart failure in which the heart becomes weakened and enlarged and cannot pump blood efficiently.

Filed Under: Business/Financial News, News Well, Stem Cells Tagged With: Aastrom Biosciences Inc, Harvest Technologies Corp.

Biocell Center inks stem cell deal with Caritas Christi hospitals

March 8, 2010 By MassDevice staff Leave a Comment

Biocell Center Corp. and Caritas Christi Health Care inked a deal to start a cryopreservation service for amniotic fluid stem cells.

The Italian biotech firm, which has its U.S. headquarters in Medford, Mass., and New England’s largest community hospital network will use Biocell’s method of preserving stem cells obtained during routine second-trimester amniocentesis procedures. The mesenchymal stem cells can be stored for decades and are believed to hold the key to treating or even eventually curing a raft of diseases. Parents can opt to preserve the cells for use in the event of future illness for themselves or their children.

Filed Under: Biotech, Business/Financial News, News Well, Stem Cells Tagged With: Biocell Center Corp.

Aastrom Biosciences back in NASDAQ’s good graces

March 5, 2010 By MedCity News Leave a Comment

By Brandon Glenn

MedCity News logo

ANN ARBOR, Mich. – Aastrom Biosciences (NSDQ:ASTMD), once in danger of being de-listed from the NASDAQ exchange, regained compliance with the exchange’s $1 minimum-share-price requirement.

Filed Under: Business/Financial News, News Well, Stem Cells Tagged With: Aastrom Biosciences Inc

Harvest Technologies completes clinical trial enrollment

November 9, 2009 By MassDevice staff Leave a Comment

Harvest Technologies Corp. completed enrollment in a clinical trial of its technique to use concentrated autologous bone marrow cells to treat patients with non-reconstructable critical limb ischemia.

Filed Under: Business/Financial News, Stem Cells

European biotech firm Biocell opens U.S. HQ in Medford, Mass.

October 23, 2009 By MassDevice staff Leave a Comment

Biocell Center Corp., the European biotech firm that pioneered a method of preserving amniotic stem cells, opened its U.S. headquarters in Medford, Mass.

Biocell CEO Kate Torchilin said the company can preserve a portion of the sample taken during amniocentesis on pregnant women, which contains stem cells that can be used to treat illness or regenerate tissue.

Filed Under: Biotech, Business/Financial News, Stem Cells

Harvest Technologies wins FDA approval for clinical trial

October 23, 2009 By MassDevice staff Leave a Comment

Harvest Technologies Corp. won approval from the Food & Drug Administration for a 42-patient trial of its technique to use concentrated autologous bone marrow cells to treat patients undergoing coronary artery bypass grafts.

The FDA’s investigational device exemption allows the Plymouth, Mass.-based firm to study whether its BMAC system can help re-grow dead or damaged heart tissue. The two phase feasibility trial will see a one patient group injected with the concentrated stem cells after CABG surgery and a control group treated with CABG alone.

Filed Under: Biotech, Business/Financial News, Stem Cells Tagged With: Tissue Regeneration

MedTech Monday: Blue dye helps repair spinal cord damage, makes rats cute

August 3, 2009 By MassDevice Leave a Comment

Blue dye helps repair spinal cord damage, turns rats into cute animals: Researchers at University of Rochester Medical Center injected mice with spinal cord injuries with a derivative of food coloring Blue Number One. The Brilliant Blue G dye, which helps control the activity of ATP by blocking its activation of P2X7 receptors, was shown to help repair the injured spinal cords — treated animals even started moving their previously paralyzed limbs.

Filed Under: Regenerative Medicine

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 50
  • Go to page 51
  • Go to page 52

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS